BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Glacet-Bernard, A.
Right arrow Articles by Soubrane, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glacet-Bernard, A.
Right arrow Articles by Soubrane, G.
Br J Ophthalmol 2000;84:609-613 ( June )

Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study

Agnès Glacet-Bernarda, Dagmar Kuhna, Andrew K Vineb, Hassiba Oubrahama, Gabriel Coscasa, Gisèle Soubranea

a University Eye Clinic of Créteil, University of Paris XII, Créteil, France, b WK Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA

Correspondence to: Agnès Glacet-Bernard, MD, University Eye Clinic of Créteil, 40, avenue de Verdun, 94000 Créteil, France agnes.glacet{at}chicreteil.fr

Accepted for publication 28 January 2000

AIMS---To study the effects of intravitreal tissue plasminogen activator (tPA) in recent onset central retinal vein occlusion (CRVO).
METHODS---15 patients with recent onset CRVO (from 1-21 days' duration, mean 8 days) were given 75-100 µg of tPA intravitreally associate with low dose low molecular weight heparin. CRVO was perfused in nine patients and with mild ischaemia not exceeding 100 disc diameters in six patients. Follow up ranged from 5 to 21 months for 14 patients (mean 8 months). Visual acuity measurement, macular threshold (Humphrey perimeter), fluorescein angiography with the scanning laser ophthalmoscope with special emphasis on retinal circulation times, and retinal perfusion were performed at days 0, 1, and 8 and months 1, 3, and 6.
RESULTS---Visual acuity was significantly improved on the first day after treatment in only one eye, and decreased transiently in six eyes (40%). Retinal blood velocity was not significantly modified by tPA injection. Retinal ischaemia developed in six eyes (43%), leading to panretinal photocoagulation in five eyes including one with rubeosis iridis. At the end of follow up, visual acuity had improved to 20/30 or better in five eyes (36%), including two with complete recovery; visual acuity was worse than 20/200 in three eyes (28%). No complication of tPA injection was observed.
CONCLUSION---Intravitreal tPA treatment for CRVO appears to be simple and safe, but did not significantly modify the course of the occlusion in our patients immediately after treatment. Final visual outcome did not differ significantly from that observed in the natural course of the disease, but final visual acuity seemed to be slightly better. A randomised study is required to determine if intravitreal tPA actually improves visual outcome in CRVO.

© 2000 by British Journal of Ophthalmology


This article has been cited by other articles:


Home page
 Br. J. Ophthalmol.Home page
T H Mahmoud, Y-W Peng, A D Proia, M Davidson, V A Deramo, and S Fekrat
Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion
Br. J. Ophthalmol., July 1, 2006; 90(7): 911 - 915.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
H Shahid, P Hossain, and W M Amoaku
The management of retinal vein occlusion: is interventional ophthalmology the way forward?
Br. J. Ophthalmol., May 1, 2006; 90(5): 627 - 639.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
J.-A. C. Pournaras, I. K. Petropoulos, J.-L. Munoz, and C. J. Pournaras
Experimental Retinal Vein Occlusion: Effect of Acetazolamide and Carbogen (95% O2/5% CO2) on Preretinal PO2
Invest. Ophthalmol. Vis. Sci., October 1, 2004; 45(10): 3669 - 3677.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
J M L, J J K, M C Cheung, and J M Lahey
Sequential treatment of central retinal vein occlusion with intravitreal tissue plasminogen activator and intravitreal triamcinolone
Br. J. Ophthalmol., August 1, 2004; 88(8): 1100 - 1101.
[Full Text] [PDF]

Home page
 Arch OphthalmolHome page
J. Garcia-Arumi, A. Boixadera, V. Martinez-Castillo, R. Castillo, A. Dou, and B. Corcostegui
Chorioretinal Anastomosis After Radial Optic Neurotomy for Central Retinal Vein Occlusion
Arch Ophthalmol, October 1, 2003; 121(10): 1385 - 1391.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
V. A. Deramo, T. A. Cox, A. B. Syed, P. P. Lee, and S. Fekrat
Vision-Related Quality of Life in People With Central Retinal Vein Occlusion Using the 25-Item National Eye Institute Visual Function Questionnaire
Arch Ophthalmol, September 1, 2003; 121(9): 1297 - 1302.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2000 by the BMJ Publishing Group Ltd.